Expression of human cytochromes P450 in chimeric mice with humanized liver

Drug Metabolism and Disposition

Volumn 32, Issue 12, 2004, Pages 1402-1410

  Katoh, Miki ^a   Matsui, Tomohito ^a   Nakajima, Miki ^a   Tateno, Chise ^b   Kataoka, Miho ^b   Soeno, Yoshinori ^c   Horie, Toru ^c   Iwasaki, Kazuhide ^d   Yoshizato, Kaisutoshi ^b,e   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c PhoenixBio USA Corporation   (Japan)

^d PFIZER INC   (United States)

^e HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN 7 HYDROXYLASE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEXAMETHASONE; DICLOFENAC;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; BLOOD DONOR; CHIMERA; CONCENTRATION RESPONSE; DNA METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER CELL; LIVER PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN RNA BINDING; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALLELES; ANIMALS; CELL TRANSPLANTATION; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GENOTYPE; HEPATOCYTES; HUMANS; IMMUNOBLOTTING; INFANT; ISOENZYMES; LIVER; MALE; MICE; MICE, TRANSGENIC; MICROSOMES, LIVER; RNA; SERUM ALBUMIN;

ANIMALIA; MURINAE;

EID: 9444259317     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001347     Document Type: Article

References (36)

1. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, and Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131-1152.
2. Brilliant MH, Gondo Y, and Eicher EM (1991) Direct molecular identification of the mouse pink-eyed unstable mutation by genome scanning. Science (Wash DC) 252:566-569.
3. Chiba K, Manabe K, Kobayashi K, Takayama Y, Tani M, and Ishizaki T (1993) Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in human liver microsomes. Eur J Clin Pharmacol 44:559-562.
4. Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR, and Gonzalez FJ (2001) The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 60:1260-1267.
5. Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, Sommer G, Rogiers X, Rogler CE, Gupta S, Will H, et al. (2001) Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33:981-988.
6. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, and Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598.
7. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, and Azuma J (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12:331-334.
8. Gomez-Lechon MJ, Donato MT, Castell JV, and Jover R (2003) Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 4:292-312.
9. Guillouzo A (1998) Liver cell models in in vitro toxicology. Environ Health Perspect 106:511-532.
10. Ingelman-Sundberg M (2002) Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 181-182:447-452.
11. Iwanari M, Nakajima M, Kizu R, Hayakawa K, and Yokoi T (2002) Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform- and cell-specific differences. Arch Toxicol 76:287-298.
12. Klose TS, Blaisdell JA, and Goldstein JA (1999) Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 13:289-295.
13. Kobayashi K, Mimura N, Fujii H, Minami H, Sasaki Y, Shimada N, and Chiba K (2000) Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res 6:3297-3303.
14. Kuehl P, Zhang J, Lin Y Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
15. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227:680-685.
16. Li AP, Kaminski DL, and Rasmussen A (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8.
17. Lu AY (1998) Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Metab Dispos 26:1217-1222.
18. Mankowski DC, Lawton MP, and Ekins S (2000) Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates. Xenobiotica 30:745-754.
19. Masubuchi Y, Iwasa T, Hosokawa S, Suzuki T, Horie T, Imaoka S, Funae Y, and Narimatsu S (1997) Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J Pharmacol Exp Ther 282:1435-1441.
20. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, et al. (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7:927-933.
21. Nakajima M, Kuroiwa Y, and Yokoi T (2002a) Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab Rev 34:865-877.
22. Nakajima M, Tane K, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2002b) Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b5 in the expression system and the differences in the marker activities. J Pharm Sci 91:952-963.
23. Nakajima M, Yoshida R, Fukami T, McLeod HL, and Yokoi T (2004) Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett 569:75-81.
24. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, and Raunio H (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203-1253.
25. Robertson GR, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, and Liddle C (2003) Transgenic mouse models of human CYP3A4 gene regulation. Mol Pharmacol 64:42-50.
26. Rodrigues AD and Rushmore TH (2003) Cytochrome P450 pharmacogenetics in drag development: in vitro studies and clinical consequences. Curr Drug Metab 3:289-309.
27. Rodriguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, and Gomez-Lechon MJ (2002) Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32:505-520.
28. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, et al. (2004) Near-completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901-912.
29. Tomlinson ES, Maggs JL, Park BK, and Back DJ (1997) Dexamethasone metabolism in vitro: species differences. J Steroid Biochem Mol Biol 62:345-352.
30. Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, and Gut I (2004) Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs and minipigs. Drug Metab Dispos 32:666-674.
31. Watanabe T, Shibata N, Westerman KA, Okitsu T, Allain JE, Sakaguchi M, Totsugawa T, Maruyama M, Matsumura T, Noguchi H, et al. (2003) Establishment of immortalized human hepatic stellate scavenger cells to develop bioartificial livers. Transplantation 75:1873-1880.
32. Wedlund PJ (2000) The CYP2C19 enzyme polymorphism. Pharmacology 61:174-183.
33. Willey TA, Bekos EJ, Gaver RC, Dunca GF, and Tay LK (1993) High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 621:231-238.
34. Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, and Yokoi T (1999a) Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27:1260-1266.
35. Yamazaki H, Tanaka M, and Shimada T (1999b) Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes. J Chromatogr B Biomed Appl 721:13-19.
36. Zhang W, Purchio AF, Chen K, Wu J, Lu L, Coffee R, Contag PR, and West DB (2003) A transgenic mouse model with a luciferase reporter for studying in vivo transcriptional regulation of the human CYP3A4 gene. Drug Metab Dispos 31:1054-1064.